Inflammasome Therapeutics

Inflammasome Therapeutics is a science-based company founded to develop therapies for prevalent, degenerative diseases such as Alzheimer’s disease, multiple sclerosis, macular degeneration and type 2 diabetes. The precise causes of these diseases are unknown; however they share many of the same risk factors – smoking, obesity, hypertension, and age. They all are multifactorial diseases with multiple biochemical factors, many shared, contributing to their progression. It is now recognized that these diseases are all characterized by upregulation of the inflammatory process, driven by prolonged activation of inflammasomes. Inflammasomes are intracellular multiprotein complexes that help trigger and maintain the inflammatory response normally as part of the innate immune system. However, in Alzheimer’s disease, multiple sclerosis, macular degeneration, and type 2 diabetes, inflammasomes become and remain activated causing the chronic release of inflammatory molecules such as caspase -1, IL-18 and IL-1β, which in turn cause progressive tissue damage and disease progression. Inflammasome Therapeutics’ focus is on reducing the dysregulation of the inflammatory process by preventing aberrant inflammasome activation.
See more

Company Offices

  • United States (headquarters)
  • Newton
  • 57 Chapel Street Suite 100 Newton, MA 02458